OncRef

Clinical Trial: NCT04513925

A Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Participants With Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC)

Status:

COMPLETED

Phase:

Phase 3

Lead Sponsor:Hoffmann-La Roche
Information Provided By:Hoffmann-La Roche
Last Update Posted:2026-06-03

Study Overview

Brief Summary

The purpose of this study is to evaluate the efficacy and safety of atezolizumab in combination with tiragolumab compared with durvalumab in participants with locally advanced, unresectable Stage III non-small cell lung cancer (NSCLC) who have received at least two cycles of concurrent platinum-based chemoradiotherapy (CRT) and have not had radiographic disease progression.

Official Title

A Phase III, Open-Label, Randomized Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Patients With Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer Who Have Not Progressed After Concurrent Platinum-Based Chemoradiation

Conditions

Non-small Cell Lung Cancer (NSCLC)

Intervention / Treatment

  • Drug: Atezolizumab
  • Drug: Tiragolumab
  • Drug: Durvalumab

Other Study ID Numbers

  • GO41854
  • 2019-004773-29
  • 2019

Start Date (Actual)

2020-08-24

Primary Completion Date (Actual)

2025-05-27

Study Completion Date (Actual)

2025-07-31

Enrollment (Actual)

829

Study Type

Interventional

Phase

Phase 3